Krystal Biotech, Inc.
One of the first gene-therapy companies to reach patients, it makes VYJUVEK, a gel applied to open wounds that treats dystrophic epidermolysis bullosa (DEB), a rare disease where skin blisters like butterfly wings. Founded in 2016 by husband-and-wife team Krish and Suma Krishnan, who self-funded its start, the company named itself "Krystal" for the clarity and precision it wanted in gene therapy.
Granted 67.2K · Sold 100.0K
Granted 67.2K · Sold 100.0K
Granted 37.9K · Sold 72.0K
Granted 18.9K · Sold 18.9K
Granted 20.6K · Sold 13.3K
Granted 1.0K · Sold 1.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Krishnan Krish SPresident and CEO, Director, 10% owner · 48 transactions | — | 6.06M | 67.2K | — | 100.0K |
| Krishnan SumaPresident, R&D, Director, 10% owner · 48 transactions | — | 6.05M | 67.2K | — | 100.0K |
| Janney DanielDirector · 23 transactions | — | 164.1K | 37.9K | — | 72.0K |
| Rossi Dino ADirector · 3 transactions | +13.8% | 89.5K | 18.9K | — | 18.9K |
| Romano KathrynChief Accounting Officer · 14 transactions | +46.3% | 22.4K | 20.6K | — | 13.3K |
| Thomas John CharlesEVP, General Counsel · 3 transactions | — | 1.0K | 1.0K | — | 1.6K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -305.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.